Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

CV Sciences (CVSI) Net Income towards Common Stockholders (2016 - 2025)

CV Sciences (CVSI) has disclosed Net Income towards Common Stockholders for 14 consecutive years, with $376000.0 as the latest value for Q4 2025.

  • Quarterly Net Income towards Common Stockholders rose 180.86% to $376000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$376000.0 through Dec 2025, up 82.37% year-over-year, with the annual reading at -$376000.0 for FY2025, 84.29% up from the prior year.
  • Net Income towards Common Stockholders hit $376000.0 in Q4 2025 for CV Sciences, up from -$382000.0 in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $5.7 million in Q1 2023 to a low of -$8.9 million in Q4 2021.
  • Historically, Net Income towards Common Stockholders has averaged -$1.2 million across 5 years, with a median of -$606000.0 in 2024.
  • Biggest five-year swings in Net Income towards Common Stockholders: tumbled 2477.5% in 2022 and later surged 476.63% in 2023.
  • Year by year, Net Income towards Common Stockholders stood at -$8.9 million in 2021, then surged by 73.89% to -$2.3 million in 2022, then surged by 62.43% to -$869000.0 in 2023, then soared by 46.49% to -$465000.0 in 2024, then surged by 180.86% to $376000.0 in 2025.
  • Business Quant data shows Net Income towards Common Stockholders for CVSI at $376000.0 in Q4 2025, -$382000.0 in Q3 2025, and -$261000.0 in Q2 2025.